SCHEMBL1879152

SCHEMBL1879152

CC(C)c1c(C(=O)O)ccn1Cc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.65
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
CYP2D6 P10635 1/20 0.44
HTT P42858 1/20 0.44
BRD4 O60885 2/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
BRDT Q58F21 1/20 0.43
ADRA1D P25100 1/20 0.42
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
EGLN1 Q9GZT9 2/20 0.40
VEGFA P15692 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1878730 0.85 NOTUM (0.51) NOTUMSMN1; SMN2KDM4ETP53CYP2D6
SCHEMBL29886767 0.85 NOTUM (0.50) NOTUMSMN1; SMN2KDM4ECYP2D6ADRA1D
SCHEMBL29886775 0.82 NOTUM (0.48) NOTUMLMNASMN1; SMN2CYP2D6ADRA1D
SCHEMBL29886703 0.79 NOTUM (0.45) NOTUMSMN1; SMN2HTTGAA
SCHEMBL3492700 0.79 NOTUM (1.00) NOTUMLMNASMN1; SMN2KDM4ETP53
SCHEMBL11439685 0.77 NOTUM (0.68) NOTUMLMNASMN1; SMN2KDM4ETP53
SCHEMBL16474374 0.77 NOTUM (0.42) NOTUMSMN1; SMN2KDM4ETP53CYP2D6
SCHEMBL29886629 0.76 TSHR (0.41) NOTUMLMNAKDM4EHTTGAA
SCHEMBL1884187 0.75 S1PR3 (0.63)
SCHEMBL3496060 0.74 NOTUM (0.64) NOTUMLMNASMN1; SMN2KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity ALLERGAN, INC. (US) 2011-05-05 US disclosed
EP-2185506-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY Allergan, Inc. (US) 2010-05-19 EP disclosed
WO-2009026407-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity S1PR1, S1PR2, S1PR3 NOTUM 822/4885LMNA 3754/4885SMN1; SMN2 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.